Friday , October 20 2017
Home / KEEP BUT DO NOT DISPLAY / Alerts / Degludec Insulin Gets EU Backing

Degludec Insulin Gets EU Backing

Degludec Insulin Gets EU Backing
Novo Nordisk’s ultra-long-acting insulin Tresiba has been recommended for approval by the European Medicines Agency in an important boost for the Danish drugmaker’s key new product. See this week’s Item #6.

First Non-Invasive CGMS Gets CE Mark Approval for People with Diabetes.
C8 MediSensors Optical Glucose Monitor System gets approval for marketing in Europe. More information coming soon.